{"id":"https://openalex.org/W7133236357","doi":"https://doi.org/10.1158/1078-0432.31442905","title":"Supplemental Figure 9 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial","display_name":"Supplemental Figure 9 from Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial","publication_year":2026,"publication_date":"2026-03-02","ids":{"openalex":"https://openalex.org/W7133236357","doi":"https://doi.org/10.1158/1078-0432.31442905"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.31442905","doi":"https://doi.org/10.1158/1078-0432.31442905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31442905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.31442905","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caron A. Jacobson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-0180-0654","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021496101","display_name":"Jason R. Westin","orcid":"https://orcid.org/0000-0002-1824-2337","observed_orcids":["https://orcid.org/0000-0002-1824-2337"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jason R. Westin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1824-2337","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081926380","display_name":"David Bernard Miklos","orcid":"https://orcid.org/0000-0003-0717-4305","observed_orcids":["https://orcid.org/0000-0003-0717-4305"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David B. Miklos","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0717-4305","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030788778","display_name":"Alex Francisco Herrera","orcid":"https://orcid.org/0000-0002-9665-7415","observed_orcids":["https://orcid.org/0000-0002-9665-7415"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alex F. Herrera","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9665-7415","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008718116","display_name":"Jerome Ritz","orcid":"https://orcid.org/0000-0001-5526-4669","observed_orcids":["https://orcid.org/0000-0001-5526-4669"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jerome Ritz","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-5526-4669","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058975989","display_name":"Scott J. Rodig","orcid":"https://orcid.org/0000-0003-1761-9769","observed_orcids":["https://orcid.org/0000-0003-1761-9769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Rodig","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1761-9769","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052568829","display_name":"Yohei Arihara","orcid":"https://orcid.org/0009-0001-7673-3724","observed_orcids":["https://orcid.org/0009-0001-7673-3724"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yohei Arihara","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-7673-3724","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027792817","display_name":"Subing Cao","orcid":"https://orcid.org/0000-0003-2416-5742","observed_orcids":["https://orcid.org/0000-0003-2416-5742"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Subing Cao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2416-5742","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085588647","display_name":"Jennifer Sun","orcid":"https://orcid.org/0009-0008-8649-3817","observed_orcids":["https://orcid.org/0009-0008-8649-3817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jennifer Sun","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-8649-3817","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041486255","display_name":"Daqin Mao","orcid":"https://orcid.org/0009-0007-2814-3969","observed_orcids":["https://orcid.org/0009-0007-2814-3969"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daqin Mao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-2814-3969","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112461283","display_name":"Sabina Adhikary","orcid":"https://orcid.org/0009-0002-7578-6223","observed_orcids":["https://orcid.org/0009-0002-7578-6223"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabina Adhikary","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-7578-6223","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121975373","display_name":"Frank Neumann","orcid":"https://orcid.org/0009-0001-0995-1537","observed_orcids":["https://orcid.org/0009-0001-0995-1537"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frank Neumann","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-0995-1537","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035796208","display_name":"Nikolay Grechko","orcid":"https://orcid.org/0009-0009-8090-9938","observed_orcids":["https://orcid.org/0009-0009-8090-9938"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nikolay Grechko","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-8090-9938","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021394406","display_name":"Frederick Lundry Locke","orcid":"https://orcid.org/0000-0001-9063-6691","observed_orcids":["https://orcid.org/0000-0001-9063-6691"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Frederick L. Locke","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9063-6691","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9550999999046326,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.03350000083446503,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00419999985024333,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/axicabtagene-ciloleucel","display_name":"axicabtagene ciloleucel","score":0.9980000257492065},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9729999899864197},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9679999947547913},{"id":"https://openalex.org/keywords/refractory-lymphoma","display_name":"refractory lymphoma","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8009999990463257},{"id":"https://openalex.org/keywords/soluble-pd-l1","display_name":"soluble PD-L1","score":0.9210000038146973},{"id":"https://openalex.org/keywords/serum-biomarkers","display_name":"serum biomarkers","score":0.6819999814033508},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.7749999761581421}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8597999811172485},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6348999738693237},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6341999769210815},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42800000309944153},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.420199990272522},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.38280001282691956},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3668999969959259},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.3522999882698059},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3495999872684479},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.29280000925064087},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.26350000500679016},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.250900000333786},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2508000135421753},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2500999867916107}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.31442905","doi":"https://doi.org/10.1158/1078-0432.31442905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31442905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.31442905","doi":"https://doi.org/10.1158/1078-0432.31442905","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.31442905","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9476000070571899,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2914767419","https://openalex.org/W3083435126","https://openalex.org/W4416187225","https://openalex.org/W7133244045","https://openalex.org/W2797193430","https://openalex.org/W4283381713","https://openalex.org/W4281838775","https://openalex.org/W4410251267","https://openalex.org/W4408810144","https://openalex.org/W4252586965"],"abstract_inverted_index":{"Correlation":[0],"between":[1],"pretreatment":[2],"tumor":[3],"PD-L1":[4,12],"H-score":[5],"and":[6],"baseline":[7],"serum":[8],"levels":[9],"of":[10],"soluble":[11]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-03-03T00:00:00"}